Literature DB >> 36227385

Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.

Fardin Nabizadeh1,2, Kasra Pirahesh3, Elham Ramezannezhad4.   

Abstract

BACKGROUND: Previous studies investigated CSF levels of α-synuclein (α-syn), amyloid-β (Aβ1-42), total tau (t-tau), and phosphorylated tau (p-tau) with clinical progression of Parkinson's disease (PD). However, there is limited data on the association between CSF biomarkers and dopamine uptake status in PD. AIM: In the current study, we aim to investigate the longitudinal association between striatal dopaminergic neuronal loss assessed by dopamine active transporter single photon emission computerized tomography (DaTSCAN) imaging with CSF α-syn, t-tau, p-tau, and Aβ1-42.
METHODS: A total of 413 early-stage PD patients and 187 healthy controls (HCs) from the PPMI. Striatal binding ratios (SBRs) of DaTSCAN images in caudate and putamen nuclei were calculated. We investigated the cross-sectional and longitudinal association between CSF biomarkers and dopamine uptake using partial correlation models adjusted for the effect of age, sex, and years of education over 24 months of follow-up.
RESULTS: The level of CSF α-syn, Aβ1-42, t-tau, and p-tau was significantly higher in HCs compared to PD groups at any time point. We found that higher CSF α-syn was associated with a higher SBR score in the left caudate at baseline (P = 0.038) and after 12 months (P = 0.012) in PD patients. Moreover, SBR scores in the left caudate and CSF Aβ1-42 were positively correlated at baseline (P = 0.021), 12 months (P = 0.006), and 24 months (P = 0.014) in patients with PD. Our findings demonstrated that change in CSF Aβ1-42 was positively correlated with change in SBR score in the left caudate after 24 months in the PD group (P = 0.043).
CONCLUSION: We found that cross-sectional levels of α-syn and Aβ1-42 could reflect the degree of dopaminergic neuron loss in the left caudate nucleus. Interestingly, longitudinal changes in CSF Aβ1-42 could predict the severity of left caudal dopaminergic neuron loss throughout the disease. This suggested that Aβ pathology might precede dopaminergic loss in striatal nuclei in this case left caudate and subsequently cognitive impairment in PD patients, although future studies are needed to confirm our results and expand the understanding of the pathophysiology of cognitive dysfunction in PD.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Alpha-synuclein; Beta-amyloid; Cerebrospinal fluid (CSF); Dopamine uptake; Parkinson’s disease; Tau

Year:  2022        PMID: 36227385     DOI: 10.1007/s10072-022-06440-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  40 in total

Review 1.  Non-motor symptoms of Parkinson's disease: diagnosis and management.

Authors:  F K Salawu; A Danburam; A B Olokoba
Journal:  Niger J Med       Date:  2010 Apr-Jun

Review 2.  Parkinson's disease. Second of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-15       Impact factor: 91.245

Review 3.  The clinical symptoms of Parkinson's disease.

Authors:  Sigurlaug Sveinbjornsdottir
Journal:  J Neurochem       Date:  2016-07-11       Impact factor: 5.372

4.  The impact of DaTscan in the diagnosis of Parkinson disease.

Authors:  Isis Gayed; Usha Joseph; Mina Fanous; David Wan; Mya Schiess; William Ondo; Kyoung-Sook Won
Journal:  Clin Nucl Med       Date:  2015-05       Impact factor: 7.794

Review 5.  Parkinson disease.

Authors:  R Balestrino; A H V Schapira
Journal:  Eur J Neurol       Date:  2019-11-27       Impact factor: 6.089

6.  The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus.

Authors:  H B Niznik; E F Fogel; F F Fassos; P Seeman
Journal:  J Neurochem       Date:  1991-01       Impact factor: 5.372

7.  Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.

Authors:  Vicky L Marshall; Cornelia B Reininger; Moritz Marquardt; Jim Patterson; Donald M Hadley; Wolfgang H Oertel; Hani T S Benamer; Paul Kemp; David Burn; Eduardo Tolosa; Jamie Kulisevsky; Luis Cunha; Durval Costa; Jan Booij; Klaus Tatsch; K Ray Chaudhuri; Gudrun Ulm; Oliver Pogarell; Helmut Höffken; Anja Gerstner; Donald G Grosset
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

8.  Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease.

Authors:  J M Wilson; A I Levey; A Rajput; L Ang; M Guttman; K Shannak; H B Niznik; O Hornykiewicz; C Pifl; S J Kish
Journal:  Neurology       Date:  1996-09       Impact factor: 9.910

9.  Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.

Authors:  Annemarie M M Vlaar; Marinus J P G van Kroonenburgh; Alfons G H Kessels; Wim E J Weber
Journal:  BMC Neurol       Date:  2007-09-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.